About AVT
Browse Articles
Authors
Customer Services

Current Issue

Displaying 11 results:

Correction

Correction: Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort

Amedeo F Capetti, Gaetana Sterrantino, Maria V Cossu, Giovanni Cenderello, Anna M Cattelan, Giuseppe V De Socio, Stefano Rusconi, Niccolò Riccardi, Gian M Baldin, Serena Cima, Fosca P Niero, Giuliano Rizzardini, Lolita Sasset

Antiviral Therapy 2017; 22:273-275


Case report

Early neuropsychological adverse events after switching from PI/r to dolutegravir could be related to hyperthyroidism in patients under levothyroxine

Jean-Luc Berger, Yohan Nguyen, Delphine Lebrun, Caroline Migault, Maxime Hentzien, Hélène Marty, Firouzé Bani-Sadr

Antiviral Therapy 2017; 22:271-272


Free
Short communication

Hepatic safety of maraviroc in patients with HIV-1 and hepatitis C and/or B virus: 144-week results from a randomized, placebo-controlled trial

Juergen K Rockstroh, Frank Plonski, Meena Bansal, Gerd Fätkenheuer, Catherine B Small, David M Asmuth, Gilles Pialoux, Rebecca Zhang-Roper, Ronnie Wang, Juan A Pineda, Jayvant Heera

Antiviral Therapy 2017; 22:263-269


Short communication

Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort

Amedeo F Capetti, Gaetana Sterrantino, Maria V Cossu, Giovanni Cenderello, Anna M Cattelan, Giuseppe V De Socio, Stefano Rusconi, Niccolò Riccardi, Gian M Baldin, Serena Cima, Fosca P Niero, Giuliano Rizzardini, Lolita Sasset

Antiviral Therapy 2017; 22:257-262


Original article

Ranpirnase eradicates human papillomavirus in cultured cells and heals anogenital warts in a Phase I study

Luis Squiquera, Debra J Taxman, Sarah A Brendle, Roberto Torres, Jamie Sulley, Thomas Hodge, Neil Christensen, David Sidransky

Antiviral Therapy 2017; 22:247-255


Original article

Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin

Fiona McPhee, Dennis Hernandez, Nannan Zhou

Antiviral Therapy 2017; 22:237-246


Free
Original article

Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV–HCV coinfection and advanced liver disease

Jürgen K Rockstroh, Patrick Ingiliz, Jörg Petersen, Markus Peck-Radosavljevic, Tania M Welzel, Marc Van der Valk, Yue Zhao, Maria Jesus Jimenez-Exposito, Stefan Zeuzem

Antiviral Therapy 2017; 22:225-236


Original article

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial

Melanie Thompson, Jacob P Lalezari, Richard Kaplan, Yvett Pinedo, Otto A Sussmann Pena, Pedro Cahn, David A Stock, Samit R Joshi, George J Hanna, Max Lataillade, the AI438011 study team

Antiviral Therapy 2017; 22:215-223


Original article

Hyperlipidaemia in HIV-infected patients on lopinavir/ritonavir monotherapy in resource-limited settings

Mitch M Matoga, Mina C Hosseinipour, Evgenia Aga, Heather J Ribaudo, Nagalingeswaran Kumarasamy, John Bartlett, Michael D Hughes, the ACTG A5230 Study Team

Antiviral Therapy 2017; 22:205-213


Original article

Evolution of renal function in African patients initiating second-line antiretroviral treatment: findings from the ANRS 12169 2LADY trial

Amandine Cournil, Arsène Hema, Sabrina Eymard-Duvernay, Laura Ciaffi, Stéphanie Badiou, Firmin N Kabore, Assane Diouf, Liliane Ayangma, Vincent Le Moing, Jacques Reynes, Sinata Koulla-Shiro, Eric Delaporte, the 2LADY Study Group

Antiviral Therapy 2017; 22:195-203


Page:
Copyright © Nucleus Global 2017. Part of Nucleus Global.
Design and Technology by Nucleus Global
Company registration No. 321 0712 (England & Wales). Registered Office address: Admiral House 76-78 Old Street, London EC1V 9AZ.